ND Industries Integration And HHC Pricing Will Secure Stability

H.B. Fuller’s analyst price target has shifted from $70.43 to $73.29. Analysts point to updated assumptions around revenue growth, profit margins, valuation multiples and recent research moves that include several price target increases and an upgraded rating.

Analyst Commentary

Recent research on H.B. Fuller highlights a mix of optimism around earnings execution and valuation, alongside caution related to the proposed Advanced Medical Solutions transaction and input cost trends.

Bullish Takeaways

• Bullish analysts are lifting price targets into the low to mid US$70s, which signals confidence that H.B. Fuller can support a higher valuation if it delivers on current assumptions for revenue and margin performance.
• JPMorgan's upgrade to Overweight, with a higher price target, reflects a view that adjusted EBITDA is improving through pricing and currency benefits even when volumes are described as flat to lower.
• Some analysts expect the upcoming quarter to be strong relative to their existing models, which they see as a support for the current P/E and for incrementally higher targets.
• Upgrades from Underweight to Neutral and then to Overweight from JPMorgan indicate that at least one large broker sees risk reward as having improved versus prior views, which can be supportive for sentiment around the stock.

Bearish Takeaways

• Bearish analysts are concerned that the potential acquisition of Advanced Medical Solutions adds risk, and have trimmed price targets to account for that deal uncertainty.
• One firm highlights the potential Advanced Medical Solutions transaction as a key factor that could drive near term share price performance, which adds an element of deal related overhang for investors to weigh.
• The same potential deal is cited as an ongoing concern even by those expecting a strong quarter, suggesting that execution risk on M&A could constrain how much investors are willing to pay for H.B. Fuller in the short term.
• Although some analysts are positive on EBITDA trends, references to flat to lower volumes emphasize that growth in the underlying demand profile is not clearly described as improving in the current commentary.

What’s in the News for H.B. Fuller

• H.B. Fuller has announced a recommended cash offer to acquire UK based Advanced Medical Solutions for approximately £715 million, valuing AMS at £2.85 per share, with the deal expected to add about $300 million in annual revenue and expand the total addressable market by $15b, subject to regulatory and shareholder approvals. (Source: recent AMS acquisition announcement)
• The company targets approximately $55 million in run rate synergies by 2031 from the Advanced Medical Solutions transaction, tied to combined revenue opportunities and cost efficiencies if the deal completes as planned. (Source: recent AMS acquisition announcement)
• Ancora Holdings Group and Ancora Holdings LLC have launched a public campaign opposing the Advanced Medical Solutions acquisition, criticizing H.B. Fuller’s leverage implications, raising concerns about integration experience, and urging the board to abandon the deal and instead conduct a full strategic review, including potential sale options. (Source: Ancora activist communications)
• UBS has raised its H.B. Fuller price target from $63 to $71 while maintaining a Neutral rating, and JPMorgan has moved to a Neutral stance, with both firms referencing the Advanced Medical Solutions bid and potential outcomes from either the transaction or a broader strategic review. (Source: UBS and JPMorgan research summary)
• H.B. Fuller has outlined plans for a new Aerospace Manufacturing Center of Excellence in Charlotte, North Carolina, expected to open in early 2027 as part of Project Quantum Leap. The facility will consolidate aerospace manufacturing, testing, and quality operations at a single site designed to meet AS9100 and targeted Nadcap standards. (Source: company business expansion announcement)

Valuation Changes for H.B. Fuller

• Fair Value: updated from $70.43 to $73.29, a modest upward adjustment of around 4.1% in the valuation model.
• Discount Rate: moved slightly from 8.30% to 8.32%, implying only a minimal change in the assumed risk profile for H.B. Fuller.
• Revenue Growth: revised from 4.44% to 7.27%, indicating higher modeled revenue expansion expectations in the latest assumptions.
• Net Profit Margin: adjusted from 6.19% to 5.73%, a reduction of roughly 0.46 percentage points in expected earnings as a share of sales.
• Future P/E: shifted from 20.56x to 19.88x, a small reduction in the assumed earnings multiple applied to H.B. Fuller.